Stephanie van Hoppe

36 Chapter 2 R E F E R E N C E S 1. Schinkel, A.H., et al., P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest, 1996. 97(11): p. 2517-24. 2. Vlaming, M.L., J.S. Lagas, and A.H. Schinkel, Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev, 2009. 61(1): p. 14-25. 3. Lockman, P.R., et al., Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res, 2010. 16(23): p. 5664-78. 4. Taskar, K.S., et al., Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res, 2012. 29(3): p. 770-81. 5. U.S. Food and Drug Administration, Approved Drugs: Afatinib . 2013; Available from: http://www.fda.gov/ Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574.htm. 6. Li, D., et al., BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008. 27(34): p. 4702-11. 7. Stopfer, P., et al., Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol, 2012. 69(4): p. 1051-61. 8. Hynes, N.E. and H.A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 2005. 5(5): p. 341-54. 9. Yarden, Y. and M.X. Sliwkowski, Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2001. 2(2): p. 127-37. 10. Di Luca, A., et al., Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment. Daru, 2015. 23: p. 40. 11. Tang, Y., et al., Afatinib inhibits proliferation and invasion and promotes apoptosis of the T24 bladder cancer cell line. Exp Ther Med, 2015. 9(5): p. 1851-1856. 12. Harbeck, N., F. Solca, and T.C. Gauler, Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. Future Oncol, 2014. 10(1): p. 21-40. 13. Wang, S.Q., et al., Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1. Oncotarget, 2015. 6(28): p. 26142-60. 14. Chung, C.H., et al., A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol, 2016. 53: p. 54-9. 15. Wang, X.K., et al., Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget, 2014. 5(23): p. 11971-85. 16. Wind, S., et al., Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clin Pharmacokinet, 2016. 17. CHMP assessment report: Giotrif . 2013; Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Public_assessment_report/human/002280/WC500152394.pdf. 18. Schouten, L.J., et al., Incidence of brainmetastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer, 2002. 94(10): p. 2698-705. 19. Sparidans, R.W., et al., Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib inmouse plasma using salting-out liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci, 2016. 1012-1013: p. 118-23. 20. Poller, B., et al., Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm, 2011. 8(2): p. 571-82. 21. Durmus, S., et al., Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm, 2012. 9(11): p. 3236-45. 22. Schinkel, A.H., et al., Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug- transporting) P-glycoproteins. Proc Natl Acad Sci U S A, 1997. 94(8): p. 4028-33. 23. Jonker, J.W., et al., The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A, 2002. 99(24): p. 15649-54.